These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 7818813)

  • 21. Immunization with gp120-depleted whole killed HIV immunogen and a second-generation CpG DNA elicits strong HIV-specific responses in mice.
    Trabattoni D; Clivio A; Bray DH; Bhagat L; Beltrami S; Maffeis G; Cesana E; Lowry P; Lissoni F; Kandimalla ER; Sullivan T; Agrawal S; Bartholomew R; Clerici M
    Vaccine; 2006 Feb; 24(9):1470-7. PubMed ID: 16221513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody to ovalbumin and delayed-type hypersensitivity to Candida albicans and mycobacteria in lactating Holstein cows using Quil A or Freund's complete adjuvant.
    Heriazon A; Thompson KA; Wilkie BN; Mathes-Sears W; Quinton M; Mallard BA
    Vet Immunol Immunopathol; 2009 Feb; 127(3-4):220-7. PubMed ID: 19054579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells.
    Trauger RJ; Ferre F; Daigle AE; Jensen FC; Moss RB; Mueller SH; Richieri SP; Slade HB; Carlo DJ
    J Infect Dis; 1994 Jun; 169(6):1256-64. PubMed ID: 7910836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses.
    Martin SJ; Vyakarnam A; Cheingsong-Popov R; Callow D; Jones KL; Senior JM; Adams SE; Kingsman AJ; Matear P; Gotch FM
    AIDS; 1993 Oct; 7(10):1315-23. PubMed ID: 8267904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor necrosis factor alpha and human immunodeficiency virus-specific functional immune responses after immunization with Gp120-depleted, inactivated HIV-1 in incomplete Freund's adjuvant (REMUNE) in HIV-1-seropositive subjects.
    Moss RB; Li L; Giermakowska WK; Lanza P; Turner JL; Wallace MR; Jensen FC; Richieri SP; Daigle AE; Theofan G; Carlo DJ
    J Hum Virol; 1998; 1(2):77-81. PubMed ID: 10195235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beta 2-microglobulin, HIV-1 p24 antibody and acid-dissociated HIV-1 p24 antigen levels: predictive markers for vertical transmission of HIV-1 in pregnant Ugandan women.
    Jackson JB; Kataaha P; Hom DL; Mmiro F; Guay L; Ndugwa C; Marum L; Piwowar E; Brewer K; Toedter G
    AIDS; 1993 Nov; 7(11):1475-9. PubMed ID: 8280414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine.
    Cooper CL; Davis HL; Morris ML; Efler SM; Krieg AM; Li Y; Laframboise C; Al Adhami MJ; Khaliq Y; Seguin I; Cameron DW
    Vaccine; 2004 Aug; 22(23-24):3136-43. PubMed ID: 15297066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maternal and newborn immunization with a human immunodeficiency virus-1 immunogen in a rodent model.
    Moss RB; Savary JR; Diveley JP; Jensen F; Carlo DJ
    Immunology; 2002 Aug; 106(4):549-53. PubMed ID: 12153518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dependence of the antibody response of guinea-pigs to collagen on the type of adjuvant and on the conformation of the antigen.
    Adelmann BC; Gentner GJ
    Z Immunitatsforsch Immunobiol; 1977 Feb; 152(5):369-80. PubMed ID: 65844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Specificity of binding of HIV-1 anti-p24 antibodies to CD4+ lymphocytes from HIV-infected subjects.
    Cameron PU; Hunter SD; Jolley D; Sonza S; Mijch A; Crowe SM
    Cytometry; 1998 Sep; 33(1):83-8. PubMed ID: 9725562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects.
    Peters BS; Cheingsong-Popov R; Callow D; Foxall R; Patou G; Hodgkin K; Weber JN
    J Infect; 1997 Nov; 35(3):231-5. PubMed ID: 9459393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques.
    Stewart VA; Walsh DS; McGrath SM; Kester KE; Cummings JF; Voss G; Delchambre M; Garçon N; Cohen JD; Heppner DG
    Vaccine; 2006 Oct; 24(42-43):6493-502. PubMed ID: 16911849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A serological screening assay of human immunodeficiency virus type 1 antibodies based on recombinant protein p24-gp41 as a fusion protein expressed in Escherichia coli.
    Mahboudi F; Irina NA; Chevalier A; Ghadiri A; Adeli A; Amini-Bavil-Olyaee S; Barkhordari F; Farzamfar B; Alinejad M
    J Biotechnol; 2006 Sep; 125(2):295-303. PubMed ID: 16647775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brief report: myeloma-associated paraprotein directed against the HIV-1 p24 antigen in an HIV-1-seropositive patient.
    Konrad RJ; Kricka LJ; Goodman DB; Goldman J; Silberstein LE
    N Engl J Med; 1993 Jun; 328(25):1817-9. PubMed ID: 8502271
    [No Abstract]   [Full Text] [Related]  

  • 36. HIV-1-Specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated, gp120-depleted HIV-1 in incomplete Freund's adjuvant.
    Moss RB; Webb E; Giermakowska WK; Jensen FC; Savary JR; Wallace MR; Carlo DJ
    J Acquir Immune Defic Syndr; 2000 Jul; 24(3):264-9. PubMed ID: 10969351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides.
    Moss RB; Diveley J; Jensen F; Carlo DJ
    Vaccine; 2000 Jan; 18(11-12):1081-7. PubMed ID: 10590329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inactivated HIV-1 Immunogen: impact on markers of disease progression.
    Moss RB; Ferré F; Trauger R; Jensen F; Daigle A; Richieri SP; Carlo DJ
    J Acquir Immune Defic Syndr (1988); 1994; 7 Suppl 1():S21-7. PubMed ID: 7910207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Humoral immunity and delayed-type hypersensitivity in healthy subjects treated for 30 days with MK-7123, a selective CXCR2 antagonist.
    Seiberling M; Kamtchoua T; Stryszak P; Ma X; Langdon RB; Khalilieh S
    Int Immunopharmacol; 2013 Oct; 17(2):178-83. PubMed ID: 23791619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Morphological studies in delayed hypersensitivity to streptococcal antigens using film preparations of the mesentery].
    Smirnova MN; Beletskaia LV
    Biull Eksp Biol Med; 1980 Aug; 90(8):195-7. PubMed ID: 6996762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.